Related Experiment Videos
Pediatric familial type II hyperlipoproteinemia: therapy with diet and colestipol resin
Insights
A low-cholesterol diet combined with colestipol effectively lowered cholesterol and LDL in children with familial hypercholesterolemia. This combination therapy normalized lipid levels in over half of the participants, showing significant therapeutic potential.
Area of Science:
- Pediatric Endocrinology
- Cardiovascular Pharmacology
- Nutritional Science
Background:
- Familial hypercholesterolemia (FH) is a genetic disorder causing high cholesterol levels from birth.
- Children with FH have an increased risk of premature cardiovascular disease.
- Effective lipid-lowering strategies are crucial for managing FH in pediatric populations.
Purpose of the Study:
- To evaluate the efficacy of a low-cholesterol diet and colestipol in reducing cholesterol and LDL in children with FH.
- To assess the safety and tolerability of this combined therapeutic approach.
Main Methods:
- A study involving 21 children heterozygous for FH.
- Measurements of total cholesterol, LDL cholesterol, and triglycerides were taken during habitual diet, low-cholesterol diet, and low-cholesterol diet plus colestipol (10 gm/day).
- Data were collected monthly over a six-month period for the dietary and combined therapy phases.
Main Results:
- Colestipol significantly reduced total cholesterol from 295 to 242 mg/100 ml and LDL from 234 to 179 mg/100 ml (p<0.05).
- Diet alone failed to normalize lipid levels in any child.
- The combination therapy normalized total and LDL cholesterol in 52% of children, with further improvements in 14-29%.
Conclusions:
- Colestipol, in conjunction with a low-cholesterol diet, is an effective and well-tolerated treatment for children with heterozygous familial hypercholesterolemia.
- This combination therapy offers a valuable therapeutic option for managing pediatric FH.
- Further research may explore long-term outcomes and optimal dosing strategies.
Abstract:
Effects of a low-cholesterol, polyunsaturate-rich diet and a synthetic organic bile sequestrant polymer (U26,597A, colestipol) were studied in 21 children, heterozygous for familial hypercholesterolemia. Total cholesterol, beta-lipoprotein cholesterol, and triglyceride were measured twice on habitual diet, monthly for six months on a low-cholesterol diet, and monthly for six months on low-cholesterol diet plus 10 gm of colestipol per day. Total cholesterol (mean +/- 1 SD) was 295 +/- 37 on habitual diet, 278 +/- 29 on low-cholesterol diet, and fell significantly to 242 +/- 29 mg/100 ml on diet plus colestipol. Low-density lipoprotein (LDL) cholesterol was 234 +/- 37 on habitual diet, 220 +/- 28 on low-cholesterol diet, and fell significantly to 179 +/- 26 mg/100 ml on diet plus drug. Plasma triglyceride levels on habitual diet were 79 +/- 31, remained unchanged on low-cholesterol diet, 86 +/- 22, and were unaffected by low-cholesterol diet plus drug, 85 +/- 17 mg/100 ml. On diet alone, plasma LDL was not normalized (less than 170 mg/100 ml) in any of the 21 children, and cholesterol fell to within normal limits (less than 230 mg/100 ml) in only one child. The combination of diet plus colestipol resin normalized total and LDL cholesterol in 52% of the children. Cholesterol was lowered to a "moderately elevated" range of 230 to 250 mg/100 ml in an additional 14% of the children and LDL was lowered to a range of 170 to 190 mg/100 ml in an additional 29%. In 33% of the children, cholesterol remained greater than 250 mg/100 ml despite diet plus colestipol, while LDL was greater than 190 mg/100 ml in 19%. Colestipol is an effective and well-tolerated cholesterol lowering compound which, in conjunction with diet, may prove to be very useful in the treatment of children heterozygous for familial hypercholesterolemia.